Viridian Therapt Rg
VRDN
USD
STOCK MARKET:
NMS
Open
 
...
Large gap with delayed quotes
Last quote
11/04/2025 - 20:48:53
Bid
11/04/2025 - 20:48:56
Bid
Volume 		Ask
11/04/2025 - 20:48:56
Ask
Volume
22.355
-0.795 ( -3.43% )
22.35
100
22.38
100
More information
Analysis by TheScreener
31.10.2025
Evaluation Slightly negative  
Interest Weak  
Sensibility High  
Analysis date: 31.10.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 15.07.2025.
Interest
  Weak
Two stars since 14.10.2025.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 14.10.2025 at a price of 20.78.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Positive
 
The dividend-adjusted forty day technical trend is positive since 15.07.2025.
4wk Rel Perf
  7.23%
 
The four-week dividend-adjusted overperformance versus SP500 is 7.23%.
Sensibility
  High
The stock has been on the high-sensitivity level since 15.07.2025.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -0.07%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 5.00%.
Mkt Cap in $bn
  2.20
With a market capitalization between $2 & $8bn, VIRIDIAN THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  0.45
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
  -12.30
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  5.57%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  13
Over the last seven weeks, an average of 13 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  73
For 1% of index variation, the stock varies on average by 0.73%.
Correlation
  0.24
Stock movements are strongly independent of index variations.
Value at Risk
  13.50
The value at risk is estimated at USD 13.50. The risk is therefore 57.12%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  15.07.2025